Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Increased by Orion Portfolio Solutions LLC

Orion Portfolio Solutions LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.7% in the 4th quarter, HoldingsChannel reports. The firm owned 90,026 shares of the biopharmaceutical company’s stock after purchasing an additional 3,224 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in Gilead Sciences were worth $8,316,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of GILD. HHM Wealth Advisors LLC increased its stake in Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership acquired a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter worth approximately $29,000. Crews Bank & Trust acquired a new stake in Gilead Sciences in the fourth quarter worth approximately $31,000. Finally, Stephens Consulting LLC boosted its stake in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on GILD shares. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a research note on Thursday, February 13th. Piper Sandler raised their price objective on shares of Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Royal Bank of Canada boosted their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Finally, Oppenheimer upped their price target on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a report on Tuesday, March 4th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $105.12.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $111.79 on Friday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The business’s 50-day moving average price is $105.48 and its two-hundred day moving average price is $94.81. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a market capitalization of $139.22 billion, a P/E ratio of 302.14, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were issued a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.83%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 302,785 shares of company stock worth $30,503,250 in the last quarter. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.